<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012217</url>
  </required_header>
  <id_info>
    <org_study_id>DX-SDY-026541</org_study_id>
    <nct_id>NCT03012217</nct_id>
  </id_info>
  <brief_title>Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2</brief_title>
  <acronym>RP2</acronym>
  <official_title>Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2 (RP2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioFire Diagnostics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioFire Diagnostics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a performance study to test the sensitivity and specificity of the BioFire FilmArray&#xD;
      Respiratory Panel (RP) 2. The purpose of this study is to prospectively collect and test&#xD;
      residual NPS specimens and generate performance data to support regulatory classification of&#xD;
      the FilmArray RP2 as an in vitro diagnostic (IVD) in the US, European Union (EU), Canada, and&#xD;
      other regions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FilmArray Respiratory Panel 2 (RP2) is an automated sample-to-answer PCR-based diagnostic&#xD;
      for the identification of common upper respiratory viral and bacterial pathogens in&#xD;
      nasopharyngeal swab (NPS) specimens collected in viral transport media (VTM). The purpose of&#xD;
      this study is to prospectively collect and test residual NPS specimens and generate&#xD;
      performance data to support regulatory classification of the FilmArray RP2 as an in vitro&#xD;
      diagnostic (IVD) in the US, European Union (EU), Canada, and other regions.&#xD;
&#xD;
      Clinical performance evaluations will be initiated at sites in the US and/or EU during the&#xD;
      2016/2017 respiratory illness season, approximately September through December.Prior to&#xD;
      performing the prospective clinical evaluation, each participating site will have the&#xD;
      necessary Institutional Review Board (IRB) reviews (or equivalent for non-U.S. sites).&#xD;
&#xD;
      Specimens for inclusion in this study will be residual, de-identified NPS collected in VTM&#xD;
      leftover from clinician-ordered respiratory pathogen testing.&#xD;
&#xD;
      Comparator testing will be performed using de-identified specimen aliquots at a central&#xD;
      reference laboratory.&#xD;
&#xD;
      This study is funded by BioFire Diagnostics, LLC. The FilmArray device conforms to the&#xD;
      requirements of the European Union In Vitro Diagnostic Directive (IVDD). This study was&#xD;
      designed such that every precaution has been taken to protect the health and safety of&#xD;
      patients, users, and other persons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sensitivity and specificity of device</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1612</enrollment>
  <condition>Upper Resp Tract Infection</condition>
  <arm_group>
    <arm_group_label>Specimens that meet inclusion criteria</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational Study</intervention_name>
    <arm_group_label>Specimens that meet inclusion criteria</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swabs.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Only residual NPS specimens from patients with clinician-ordered respiratory pathogen&#xD;
        testing will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Specimen is residual NPS in VTM left over from standard of care testing under&#xD;
             clinician order for respiratory pathogen analysis&#xD;
&#xD;
          -  Specimen has been held at appropriate temperature&#xD;
&#xD;
          -  Sufficient volume remaining after standard of care testing and available for use in&#xD;
             the study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Specimen other than NPS in VTM (e.g. nasopharyngeal aspirate, anterior or midturbinate&#xD;
             swab, oropharyngeal swab, NPS collected in medium other than VTM)&#xD;
&#xD;
          -  Specimen cannot be tested within the defined storage parameters&#xD;
&#xD;
          -  Insufficient specimen volume for testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

